By Gilang Cahya 
A groundbreaking noninvasive colorectal cancer screening test, conveniently administered at home, has demonstrated the potential to significantly reduce colorectal cancer-related deaths by an impressive 33%, according to a landmark study recently published in the esteemed journal JAMA Network Open. This pioneering research marks the first time the effectiveness of such a tool has been rigorously evaluated across diverse racial demographics, offering critical insights into its potential to address health disparities.
The comprehensive study, conducted by researchers from The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute (OSUCCC — James) in collaboration with Kaiser Permanente, meticulously analyzed data from nearly 11,000 patients. These individuals underwent at-home Fecal Immunochemical Testing (FIT) between 2002 and 2017 as members of Kaiser Permanente’s extensive network in Northern and Southern California. Kaiser Permanente, a recognized leader in healthcare delivery, has been at the forefront of implementing large-scale at-home colorectal cancer screening programs, aiming to elevate overall screening compliance and actively work towards closing existing racial disparity gaps in cancer outcomes.
The Critical Need for Accessible Screening
"The most effective screening test is undeniably the one that actually gets done, and done correctly," emphasized Dr. Chyke Doubeni, the study’s senior author. Dr. Doubeni, who also serves as Chief Equity Officer at the Wexner Medical Center, Associate Director of Diversity, Equity, and Inclusion at the OSUCCC — James, and a distinguished professor at The Ohio State University College of Medicine, highlighted the persistent challenge of under-screening. "For decades, we have known that colorectal cancer can be detected in its earliest, precancerous stages through routine screening. Yet, tragically, only about 60% of Americans between the ages of 45 and 75 are up to date with their recommended screenings. This shortfall represents a significant public health concern, as we possess the knowledge and tools to save many more lives by simply enhancing the accessibility of screening, particularly through non-invasive methods like FIT."
Dr. Doubeni further elaborated on the psychological barriers that can impede individuals from undergoing recommended screenings. "A significant number of people may forgo a colonoscopy due to apprehension or embarrassment," he stated. "This avoidance often leads to diagnoses occurring at more advanced, and consequently less treatable, stages of the disease."
FIT: A Powerful and Comparable Alternative
The study’s findings offer strong empirical support for the efficacy of FIT as a viable screening modality. "The evidence unequivocally shows that performing FIT annually is as effective as undergoing a colonoscopy every ten years for individuals at average risk," Dr. Doubeni asserted. "This study should instill confidence in both individuals and their clinicians to embrace this non-invasive test for screening. Furthermore, it underscores the importance of developing strategies to deploy these tests effectively in underserved communities, where colorectal cancer screening rates are often alarmingly low."
He underscored a crucial caveat: "It is absolutely critical that anyone with a positive FIT result does not delay in scheduling a follow-up colonoscopy. A screening colonoscopy is a procedure where a flexible tube equipped with a tiny camera is gently inserted into the rectum to visualize the lining of the intestines. This allows for the immediate removal of precancerous polyps and the treatment of early-stage cancers before they can progress to advanced stages." The FIT test itself is a straightforward process, involving the collection of a stool sample at home, which is then mailed to a laboratory for analysis.
Study Design and Key Findings
The rigorous methodology of the study involved the evaluation of data from 10,711 individuals who completed a FIT screening for colorectal cancer. The participants, aged between 52 and 85 years, were drawn from multiple medical centers and were part of Kaiser Permanente’s patient population between 2002 and 2017.
The most striking outcome of the research was the significant 33% reduction in the risk of colorectal cancer-related death observed among those who participated in the FIT screening program. Beyond the overall mortality reduction, the study also revealed a notable 42% lower risk of developing cancers located on the left side of the colon, a category that includes rectal cancers. Crucially, FIT screening was associated with a reduced risk of colorectal cancer death across various racial groups, including non-Hispanic Asian, non-Hispanic Black, and non-Hispanic White individuals.
"Colorectal cancer screening is a proven lifesaver and stands as one of the most effective strategies for decreasing mortality from this disease," stated Dr. Douglas Corley, a co-principal investigator for the study and Chief Research Officer at Kaiser Permanente, Northern California. "This study, which examined at least one FIT screening within the past few years, unequivocally confirms its efficacy as a screening tool. Its convenience for home-based administration is a significant advantage, and we anticipate that regular, annual use, as recommended, will lead to even more substantial reductions in cancer deaths over time. In our experience at Kaiser Permanente, offering multiple screening options has successfully increased participation rates to over 80%, which has been directly linked to an approximate 50% reduction in colorectal cancer deaths."
Addressing Disparities: A Timeline of Progress and Future Directions
The impetus for this research stems from a long-standing recognition of disparities in colorectal cancer incidence and mortality. Historically, certain populations have faced greater burdens from this disease. For instance, the American Cancer Society reports that Black patients are 20% more likely to be diagnosed with colon cancer and 40% more likely to die from the disease compared to non-Hispanic white patients. Similarly, individuals residing in the Appalachian region have disproportionately high rates of death from colorectal cancer.
Recognizing these inequities, healthcare providers and researchers have been actively seeking more effective and accessible screening solutions. The development and implementation of at-home FIT testing represent a significant stride in this ongoing effort. Kaiser Permanente’s initiative to integrate FIT into its large-scale screening programs, beginning in the early 2000s, exemplifies a commitment to proactive public health. This study’s findings, building upon years of data collection and patient participation, provide the most robust evidence to date of FIT’s impact on mortality, particularly across diverse racial groups.
The Wexner Medical Center and the OSUCCC — James have also embraced this evidence-based approach. They have launched a pilot program to provide at-home colorectal cancer screening tests, a crucial step that is now being integrated into their primary care clinics. This initiative signifies a broader commitment to expanding screening access and ensuring that these life-saving tools reach those who need them most.
Implications for Public Health and Clinical Practice
The implications of this study are far-reaching for public health policy, clinical practice, and individual patient care. The clear demonstration of FIT’s effectiveness in reducing mortality, coupled with its non-invasive nature and home-based administration, makes it an ideal tool for widespread adoption. This is particularly relevant for populations that face barriers to traditional screening methods, such as those with limited access to transportation, inflexible work schedules, or significant apprehension about invasive procedures.
The study’s confirmation of FIT’s efficacy across racial groups offers a powerful argument for its targeted deployment in communities with historically lower screening rates and higher cancer mortality. By providing accessible and effective screening options, healthcare systems can begin to dismantle the systemic inequities that contribute to these disparities.
Furthermore, the findings provide clinicians with strong, evidence-based justification for recommending annual FIT screening for average-risk individuals, positioning it as a comparable and often more practical alternative to biennial colonoscopies. The emphasis on the critical importance of follow-up colonoscopies for positive FIT results remains paramount, ensuring that the screening process leads to timely diagnosis and treatment.
Future Outlook and Collaborative Efforts
The collaborative nature of this research, involving leading institutions like The Ohio State University and Kaiser Permanente, highlights the power of interdisciplinary partnerships in advancing cancer research. The study’s findings are expected to fuel further research into optimizing FIT screening protocols, exploring its utility in different age groups, and developing innovative strategies for patient engagement and follow-up.
The National Cancer Institute’s support for this study underscores its significance in the national agenda for cancer prevention and control. The researchers involved, including Dr. Douglas Corley, Dr. Christopher Jensen, Dr. Theodore Levin, Dr. Nirupa Ghai, Kimberly Cannavale, Wei Zhao, Kevin Selby, Skye Buckner-Petty, MPH, Dr. Ann Zauber, Dr. Robert Fletcher, Dr. Noel Weiss, and Dr. Joanne Schottinger, represent a dedicated cohort of scientists committed to reducing the burden of colorectal cancer.
In conclusion, this pivotal study in JAMA Network Open offers a beacon of hope in the fight against colorectal cancer. By validating the substantial mortality reduction achievable with a noninvasive, at-home screening test like FIT, it provides a clear pathway towards increasing screening rates, addressing health disparities, and ultimately saving countless lives. The continued implementation and expansion of such accessible screening initiatives are crucial for achieving a future where colorectal cancer is detected earlier and treated more effectively across all populations.
